Skip to content

Institutional Registry of Haemorrhagic Hereditary Telangiectasia

Institutional Registry of Haemorrhagic Hereditary Telangiectasia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01761981
Enrollment
590
Registered
2013-01-07
Start date
2010-01-01
Completion date
2035-12-01
Last updated
2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haemorrhagic Hereditary Telangiectasia

Keywords

Haemorrhagic Hereditary Telangiectasia, Rendu Osler Weber Syndrome, Osler Weber Rendu Syndrome, HHT

Brief summary

The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis, treatment, monitoring and survival. This study will also describe the occurrence of Haemorrhagic Hereditary Telangiectasia in the population of HIBA in the Central Hospital, as well as the characteristics of clinical presentation and evolution.

Detailed description

Haemorrhagic Hereditary Telangiectasia is a uncommon autosomic hereditary disorder caracterizad for recurrent epistaxis,cutaneomucous telangiectasias and arteriovenous malformations in diferent organs; brain, lung, liver and gastrointestinal are more often afected . Afect one in 5000-8000 individual in worldwide. HHT may produce important morbidity like brain absces, stroke, hemoptisis and cronic ferropenic anemia. Molecular mechanism of this disorder are complex and still no fully dilucidated. The genes mutated in HHT encode endothelial cell-expressed proteins that mediate signalling by the transforming growth factor (TGF)b superfamily. Endoglin (HHT type I) and ACVRL-1 (HHT type 2) mutations are responsible in more than 80% of the individuals. Mutation of SMAD 4 protein (MADH4)cause HHT in association with juvenile polyposis. HHT may associated with primary pulmonary hypertension en more rare cases. There are not HHT registry in Argentina and Latinamerican population. This registry may gader valious information in order to generate a better diagnosis and treatment of our population and others.

Interventions

None listed

Sponsors

Hospital Italiano de Buenos Aires
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patients with HHT defined. 2. Followed in Unidad HHT of Hospital Italiano de Buenos Aires.

Exclusion criteria

1\. Denied to participated in the registry or inform consent process.

Design outcomes

Primary

MeasureTime frameDescription
morbidity1 yearControl visit every three month

Countries

Argentina

Contacts

CONTACTMarcelo M Serra, MD
marcelo.serra@hospitalitaliano.org.ar+541149590200
CONTACTDiego H Giunta, MD
diego.giunta@hospitalitaliano.org.ar+541149590200
PRINCIPAL_INVESTIGATORMarcelo M Serra, MD

HHT Center of Excelence Hospital Italiano de Buenos Aires

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026